EDIT vs. CRSP

Last updated Jun 4, 2026

EDIT (Editas Medicine, Inc.) and CRSP (CRISPR Therapeutics AG) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, EDIT returned -39.28%/yr vs -14.40%/yr for CRSP. A 0.66 correlation means they provide meaningful diversification when combined.

Performance

EDIT vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Editas Medicine, Inc. (EDIT) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, EDIT achieves a 35.61% return, which is significantly higher than CRSP's -0.69% return.

EDIT

• 1D: -1.42%
• 1M: -7.33%
• YTD: 35.61%
• 6M: 17.55%
• 1Y: 52.75%
• 3Y*: -34.00%
• 5Y*: -39.28%
• 10Y*: -22.08%

CRSP

• 1D: 0.12%
• 1M: -2.80%
• YTD: -0.69%
• 6M: -6.98%
• 1Y: 36.91%
• 3Y*: -7.12%
• 5Y*: -14.40%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

EDIT vs. CRSP - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
EDIT Editas Medicine, Inc.	35.61%	61.42%	-87.46%	14.21%	-66.59%	-62.13%	136.78%	30.15%	-25.97%	89.34%
CRSP CRISPR Therapeutics AG	-0.69%	33.23%	-37.12%	54.00%	-46.36%	-50.51%	151.39%	113.18%	21.68%	15.89%

Correlation

The correlation between EDIT and CRSP is 0.64, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.64
Correlation (3Y) Calculated over the trailing 3-year period	0.66
Correlation (5Y) Calculated over the trailing 5-year period	0.71
Correlation (All Time) Calculated using the full available price history since Oct 20, 2016	0.66

The correlation between EDIT and CRSP has been stable across timeframes, ranging from 0.64 to 0.71 - a consistent structural relationship.

Fundamentals

Market Cap EDIT : $272.10M CRSP : $5.00B
EPS EDIT : -$1.21 CRSP : -$6.24
PS Ratio EDIT : 7.00 CRSP : 1.16K
PB Ratio EDIT : 61.73 CRSP : 2.76
Total Revenue (TTM) EDIT : $35.86M CRSP : $4.10M
Gross Profit (TTM) EDIT : $35.86M CRSP : -$171.17M
EBITDA (TTM) EDIT : -$76.66M CRSP : -$509.21M

Return for Risk

EDIT vs. CRSP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EDIT

EDIT Risk / Return Rank: 61
EDIT Sharpe Ratio Rank: 60
EDIT Sortino Ratio Rank: 65
EDIT Omega Ratio Rank: 62
EDIT Calmar Ratio Rank: 59
EDIT Martin Ratio Rank: 57

CRSP

CRSP Risk / Return Rank: 58
CRSP Sharpe Ratio Rank: 60
CRSP Sortino Ratio Rank: 60
CRSP Omega Ratio Rank: 56
CRSP Calmar Ratio Rank: 59
CRSP Martin Ratio Rank: 55

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

EDIT vs. CRSP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Editas Medicine, Inc. (EDIT) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	EDIT	CRSP	Difference
Sharpe ratio Return per unit of total volatility	0.56	0.60	-0.04
Sortino ratio Return per unit of downside risk	1.50	1.28	+0.22
Omega ratio Gain probability vs. loss probability	1.17	1.15	+0.02
Calmar ratio Return relative to maximum drawdown	0.89	0.88	+0.01
Martin ratio Return relative to average drawdown	1.58	1.49	+0.10
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

EDIT vs. CRSP - Sharpe Ratio Comparison

The current EDIT Sharpe Ratio is 0.56, which is comparable to the CRSP Sharpe Ratio of 0.60. The chart below compares the historical Sharpe Ratios of EDIT and CRSP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	EDIT	CRSP	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.56	0.60	-0.04
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.42	-0.24	-0.18
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.26	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.20	0.23	-0.42

Drawdowns

EDIT vs. CRSP - Drawdown Comparison

The maximum EDIT drawdown since its inception was -98.92%, which is greater than CRSP's maximum drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for EDIT and CRSP.

Drawdown Indicators

	EDIT	CRSP	Difference
Max Drawdown Largest peak-to-trough decline	-98.92%	-85.11%	-13.81%
Max Drawdown (1Y) Largest decline over 1 year	-59.88%	-42.25%	-17.63%
Max Drawdown (3Y) Largest decline over 3 years	-91.46%	-64.91%	-26.55%
Max Drawdown (5Y) Largest decline over 5 years	-98.66%	-80.68%	-17.98%
Max Drawdown (10Y) Largest decline over 10 years	-98.92%	—	—
Current Drawdown Current decline from peak	-96.93%	-75.20%	-21.73%
Average Drawdown Average peak-to-trough decline	-62.56%	-49.17%	-13.39%
Ulcer Index Depth and duration of drawdowns from previous peaks	33.47%	24.92%	+8.55%

Volatility

EDIT vs. CRSP - Volatility Comparison

Editas Medicine, Inc. (EDIT) has a higher volatility of 30.18% compared to CRISPR Therapeutics AG (CRSP) at 14.90%. This indicates that EDIT's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	EDIT	CRSP	Difference
Volatility (1M) Calculated over the trailing 1-month period	30.18%	14.90%	+15.28%
Volatility (6M) Calculated over the trailing 6-month period	61.46%	42.49%	+18.97%
Volatility (1Y) Calculated over the trailing 1-year period	94.33%	61.68%	+32.65%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	93.99%	60.46%	+33.53%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	83.75%	64.27%	+19.48%

Dividends

EDIT vs. CRSP - Dividend Comparison

Neither EDIT nor CRSP has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both EDIT and CRSP in my portfolio?

EDIT and CRSP have a correlation of 0.64, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, EDIT or CRSP?

EDIT has higher volatility (30.18%) compared to CRSP (14.90%). In terms of maximum drawdown, EDIT dropped -98.92% vs CRSP's -85.11%.

Which has better risk-adjusted returns?

CRSP currently has the higher Sharpe Ratio (0.60 vs 0.56), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.